Molecular structure of GW8510, CAS Number: 222036-17-1
GW8510 (CAS 222036-17-1)
See product citations (8)
Alternate Names:
4-{[(7-Oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)methyl]amino}-N-(2-pyridyl)benzenesulfonamide
Application:
GW8510 is an inhibitor of Cdk2 (cyclin kinase 2)
CAS Number:
222036-17-1
Purity:
≥97%
Molecular Weight:
449.51
Molecular Formula:
C21H15N5O3S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
GW8510 is a compound frequently utilized in biochemical studies, particularly those focusing on cell cycle progression. It acts as a specific inhibitor of cyclin-dependent kinase 2 (CDK2), a key enzyme that regulates the transition from the G1 to the S phase of the cell cycle. Researchers employ GW8510 to understand the molecular mechanisms of cell division and to identify potential targets for intervention in uncontrolled cell proliferation. Its inhibitory effect on CDK2 makes it useful in assays designed to evaluate the role of this kinase in various cellular processes. Moreover, GW8510 is often used in signal transduction experiments to dissect pathways involved in cell growth and regulation.
GW8510 (CAS 222036-17-1) References
- GW8510 increases insulin expression in pancreatic alpha cells through activation of p53 transcriptional activity. | Fomina-Yadlin, D., et al. 2012. PLoS One. 7: e28808. PMID: 22242153
- Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. | Alvarez, G., et al. 2012. J Neurosci Res. 90: 1020-9. PMID: 22252837
- Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma. | Chung, FH., et al. 2014. PLoS One. 9: e86299. PMID: 24475102
- Quantitative-proteomic comparison of alpha and Beta cells to uncover novel targets for lineage reprogramming. | Choudhary, A., et al. 2014. PLoS One. 9: e95194. PMID: 24759943
- Cell-based assays for Parkinson's disease using differentiated human LUHMES cells. | Zhang, XM., et al. 2014. Acta Pharmacol Sin. 35: 945-56. PMID: 24989254
- Gene Expression-Based Screen for Parkinson's Disease Identifies GW8510 as a Neuroprotective Agent. | Wimalasena, NK., et al. 2016. ACS Chem Neurosci. 7: 857-63. PMID: 27270122
- Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. | Chen, P., et al. 2018. Clin Sci (Lond). 132: 1417-1433. PMID: 29853661
- The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. | Kidnapillai, S., et al. 2020. World J Biol Psychiatry. 21: 775-783. PMID: 29956574
- EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. | Tabbal, H., et al. 2019. Br J Cancer. 121: 384-394. PMID: 31363169
- Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer. | Rüstem, DG., et al. 2021. Anticancer Agents Med Chem. 21: 2204-2215. PMID: 33397269
- Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. | Liu, W., et al. 2021. Nat Commun. 12: 4961. PMID: 34400640
- Expression and clinical significance of TIMELESS in glioma. | Ren, Z., et al. 2021. Int J Clin Exp Pathol. 14: 938-955. PMID: 34646412
- Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. | Xu, T., et al. 2022. Front Oncol. 12: 820696. PMID: 35756622
Inhibitor of:
Cdk2, Coronin 1B, D14Ertd449e, E2F-3, MITF, and PGF2αR.Activator of:
Cdk3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GW8510, 1 mg | sc-215122 | 1 mg | $293.00 | |||
GW8510, 5 mg | sc-215122A | 5 mg | $626.00 |